Category Archives: ASCOupdate

4. ASCOupdate 2011, Urogenitale Tumore

Diskussionsleiter Dr. R. Cathomas, Kantonsspital Chur, bespricht folgende Studien:

Abstract 4514: A phase III randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/ UK Intercontinental Trial CRUKE/01/013)

Abstract 4503: Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial

Abstract 4512: Toward a rational strategy for prostate cancer screening based on long-term risk of prostate cancer metastases and death: Data from a large, unscreened, population-based cohort followed for up to 30 years

Abstract 4509: A randomized phase III study comparing paclitaxel-BEP (T-BEP) to standard BEP in patients with in intermediate prognosis germ cell cancer (GCC): An intergroup study of EORTC, German TCSG/AUO, MRC, and Spanish GCC group (EORTC 30983)

Abstract 4516: Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial

4. ASCOupdate 2011, Lymphoma und Myeloma

Diskussionsleiter Dr. L. Widmer, OnkoZentrum Hirslanden, Zürich, bespricht folgende Studien:

Abstract 8000: R-CHOP14 versus R-CHOP21: Result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma

Abstract 8002: Conventional chemoimmunotherapy (R-CHOEP-14) or high-dose therapy (R-Mega-CHOEP) for young, high-risk patients with aggressive B-cell lymphoma: Final results of the randomized Mega-CHOEP trial of the German High-Grade Non-Hodgkin Lymphona Study Group (DSHNHL)

Abstract 8010: Does zoledronic acid (ZOL) reduce skeletal-related events (SREs) and improve progression-free survival (PFS) in patients (Pts) with multiple myeloma (MM) with or without bone disease? MRC myeloma IX study results

Abstract 8009: Secondary Malignancies Following Multiple Myeloma

Abstract LBA4: Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma

Abstract LBA5: Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma

4. ASCOupdate 2011, Gastrointestinale Tumore

Diskussionsleiter Dr. D. Helbling, OnkoZentrum Zürich, bespricht folgende Studien:

Abstract 3520: An Ontario Clinical Oncology Group (OCOG) randomized controlled trial (RCT) assessing FDG PET/CT in resectable liver colorectal adenocarcinoma metastases (CAM)

Abstract LBA1: Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO)

Abstract LBA4002: Adjuvant capecitabine and oxaliplatin for gastric cancer: Results of the phase III CLASSIC trial

Abstract 4000: Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC)

Abstract 4004: A multicenter, randomized phase III trial comparing second-line chemotherapy (SLC) plus best supportive care (BSC) with BSC alone for pretreated advanced gastric cancer (AGC)

Abstract 3511: Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab

4. ASCOupdate 2011, Brust- und gynäkologische Tumore

Diskussionsleiter Dr. A. Müller, Kantonsspital Winterthur, bespricht folgende Studien:

Abstract LBA 504: Exemestane for primary prevention of breast cancer in postmenopausal women: NCIC CTG MAP.3-A randomized placebo-controlled clinical trial

Abstract 509: LANDSCAPE: An FNCLCC phase II study with lapatinib (L) and capecitabine (C) in patients with brain metastases (BM) from HER2-positive metastatic breast cancer (MBC) before whole brain radiotherapy (WBR)

Abstract LBA1003: NCIC-CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer

Abstract 1007: A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC)

Abstract LBA5006: Result of interim analysis of overall survival in the GCIG ICON7 phase III randomised trial of bevacizumab in women with newly diagnosed ovarian cancer

Abstract LBA5007: OCEANS: A randomized, double-blinded, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinumsensitive recurrent epithelial ovarian(EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC)

4. ASCOupdate 2011, Lungentumore

Diskussionsleiter: Dr. M. Früh, Kantonsspital St. Gallen, bespricht folgende Studien:

Abstract CRA7510: PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC)

Abstract 7503: Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial

Abstract 7507: Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls

Abstract 2501: Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC)

Abstract 7000: Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC).